TDP-43 pathology in familial frontotemporal dementia and motor neuron disease without Progranulin mutations
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Frontotemporal dementia is accompanied by motor neuron disease (FTD + MND) in approximately 10% of cases. There is accumulating evidence for a clinicopathological overlap between FTD and MND based on observations of familial aggregation and neuropathological findings of ubiquitin-positive neuronal cytoplasmatic inclusions (NCI) in lower motor neurons, hippocampus and neocortex in both conditions. Several familial forms exist with different genetic loci and defects. We investigated the familial aggregation and clinical presentation of FTD + MND cases in a large cohort of 368 FTD patients in The Netherlands. Immunohistochemistry of available brain tissue of deceased patients was investigated using a panel of antibodies including ubiquitin, p62 and TAR DNA-binding protein of 43 kDa antibodies. A total of eight patients coming from six families had a family history positive for FTD + MND (mean age at onset 53.2 +/- 8.4 years). Five patients presented with behavioural changes and cognitive changes followed by motor neuron disease, whereas symptoms of motor neuron disease were the presenting features in the remaining three patients. Other affected relatives in these families showed dementia/FTD, MND or FTD + MND reflecting the clinical interfamilial variation. No mutations were identified in any of the candidate genes, including Superoxide Dismutase 1, dynactin, angiogenin, Microtubule-Associated Protein Tau, valosin-containing protein and progranulin. Available brain tissue of five patients with familial FTD + MND showed NCI in hippocampus, neocortex and spinal cord in all, and neuronal intranuclear inclusions (NII) in two brains. TDP-43 antibody showed robust staining of neuronal inclusions similar in distribution and morphology to NCI and NII. Additionally, TDP-43 antibody also stained ubiquitin-negative glial inclusions in the basal striatum of one case. In conclusion, there exists considerable clinical variation within families with FTD + MND, which may be determined by other genetic or environmental factors. NII are also found in some cases of familial FTD + MND without Progranulin mutations. The observation of glial TDP-43 positive inclusions in one brain is very interesting, although their pathophysiological significance is yet unknown.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
Arai, T., Hasegawa, M., Akiyama, H., Ikeda, K., Nonaka, T., Mori, H., Mann, D., Tsuchiya, K., Yoshida, M., Hashizume, Y., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.093 · Cited by 2,732
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058
Cruts, M., Gijselinck, I., van der Zee, J., Engelborghs, S., Wils, H., Pirici, D., Rademakers, R., Vandenberghe, R., Dermaut, B., Martin, J.-J., et al. (2006) · Nature · doi:10.1038/nature05017 · Cited by 1,512 · cited 4×
“, 2005), in hereditary FTD with and without progranulin (PGRN) mutations (Rosso et al., 2001a; Baker et al., 2006; Cruts et al., 2006) and in semantic dementia (Rossor et al.”
BackgroundInfluentialWatts, G. D. J., Wymer, J., Kovach, M. J., Mehta, S. G., Mumm, S., Darvish, D., Pestronk, A., Whyte, M. P., & Kimonis, V. E. (2004) · Nature Genetics · doi:10.1038/ng1332 · Cited by 1,391 · cited 3×
“Other genetic loci for FTDþMND are found on chromosome 9p (Watts et al., 2004; Morita et al., 2006; Vance et al., 2006), 9q (Hosler et al., 2000) and 17q (Wilhelmsen et al., 2004).”
BackgroundClinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups.
(1994) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.4.416 · Cited by 1,331 · cited 3×
“The diagnosis FTD was based on the criteria of Lund and Manchester (Neary et al., 1998; The Lund and Manchester Groups, 1994) and included (1) a progressive behavioural disorder with insidious onset; (2) affective symptoms; (3) speech disorder; (4) preserved spatial orientation and praxis and (5)…”
MethodMutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia
Skibinski, G., Parkinson, N. J., Brown, J. M., Chakrabarti, L., Lloyd, S. L., Hummerich, H., Nielsen, J. E., Hodges, J. R., Spillantini, M. G., Thusgaard, T., et al. (2005) · Nature Genetics · doi:10.1038/ng1609 · Cited by 822 · cited 4×
“Several genetic defects have been identified, including Chromatin-Modifying Protein 2b gene (CHMP2B) (Skibinski et al., 2005; Parkinson et al., 2006), and dynactin gene (DCTN1) (Munch et al., 2005).”
BackgroundInfluentialALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B)
Parkinson, N., Ince, P. G., Smith, M. O., Highley, R., Skibinski, G., Andersen, P. M., Morrison, K. E., Pall, H. S., Hardiman, O., Collinge, J., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000231510.89311.8b · Cited by 395
Cited by
Converging Mechanisms in ALS and FTD: Disrupted RNA and Protein Homeostasis
Ling, S.-C., Polymenidou, M., & Cleveland, D. W. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.033 · Cited by 1,811
TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration
Lagier-Tourenne, C., Polymenidou, M., & Cleveland, D. W. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq137 · Cited by 1,021
Winton, M. J., Igaz, L. M., Wong, M. M., Kwong, L. K., Trojanowski, J. Q., & Lee, V. M.-Y. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800342200 · Cited by 659
Clinical, genetic and pathological heterogeneity of frontotemporal dementia: A review
Seelaar, H., Rohrer, J. D., Pijnenburg, Y. A. L., Fox, N. C., & van Swieten, J. C. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.212225 · Cited by 609
“Motor neuron disease (MND) may occur early or late in the disease course in a subset of FTD patients.(65) 66 Muscle atrophy, weakness and fasciculations are often most prominent in the upper extremities and the tongue.”
BackgroundSelf-citationSnowden, J. S., Rollinson, S., Thompson, J. C., Harris, J. M., Stopford, C. L., Richardson, A. M. T., Jones, M., Gerhard, A., Davidson, Y. S., Robinson, A., et al. (2012) · Brain · doi:10.1093/brain/awr355 · Cited by 523
Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease
Buratti, E. (2008) · Frontiers in Bioscience · doi:10.2741/2727 · Cited by 491
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases
Nakashima-Yasuda, H., Uryu, K., Robinson, J., Xie, S. X., Hurtig, H., Duda, J. E., Arnold, S. E., Siderowf, A., Grossman, M., Leverenz, J. B., et al. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0261-2 · Cited by 468
“of these Wndings [5, 6, 17, 27] including evidence that TDP-43 proteinopathy underlies most or all FTLD-U caused by progranulin gene mutations [16, 26], at least some cases of Guam parkinsonism–dementia complex [13], and many cases of AD with and without prominent hippo-”
BackgroundHigashi, S., Iseki, E., Yamamoto, R., Minegishi, M., Hino, H., Fujisawa, K., Togo, T., Katsuse, O., Uchikado, H., Furukawa, Y., et al. (2007) · Brain Research · doi:10.1016/j.brainres.2007.09.048 · Cited by 419
The two faces of protein misfolding: gain‐ and loss‐of‐function in neurodegenerative diseases
Winklhofer, K. F., Tatzelt, J., & Haass, C. (2008) · The EMBO Journal · doi:10.1038/sj.emboj.7601930 · Cited by 401
TDP‐43, the signature protein of FTLD‐U, is a neuronal activity‐responsive factor
Wang, I. ‐., Wu, L., Chang, H., & Shen, C. ‐. J. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05190.x · Cited by 335
TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration
Benajiba, L., Le Ber, I., Camuzat, A., Lacoste, M., Thomas‐Anterion, C., Couratier, P., Legallic, S., Salachas, F., Hannequin, D., Decousus, M., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21612 · Cited by 303
The genetics and neuropathology of frontotemporal lobar degeneration
Sieben, A., Van Langenhove, T., Engelborghs, S., Martin, J.-J., Boon, P., Cras, P., De Deyn, P.-P., Santens, P., Van Broeckhoven, C., & Cruts, M. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1029-x · Cited by 280
“The reported heritability of FTLD-ALS is high: approximately 50 % is considered familial [56, 132, 141].”
BackgroundFTD and ALS: A Tale of Two Diseases
Ferrari, R., Kapogiannis, D., D. Huey, E., & Momeni, P. (2011) · Current Alzheimer Research · doi:10.2174/156720511795563700 · Cited by 272
The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions
Simón-Sánchez, J., Dopper, E. G. P., Cohn-Hokke, P. E., Hukema, R. K., Nicolaou, N., Seelaar, H., de Graaf, J. R. A., de Koning, I., van Schoor, N. M., Deeg, D. J. H., et al. (2012) · Brain · doi:10.1093/brain/awr353 · Cited by 270
Self-citationNelson, P. T., Abner, E. L., Schmitt, F. A., Kryscio, R. J., Jicha, G. A., Smith, C. D., Davis, D. G., Poduska, J. W., Patel, E., Mendiondo, M. S., et al. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00244.x · Cited by 239
van Swieten, J. C., & Heutink, P. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70194-7 · Cited by 234
Self-citationIncreased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis
Kasai, T., Tokuda, T., Ishigami, N., Sasayama, H., Foulds, P., Mitchell, D. J., Mann, D. M. A., Allsop, D., & Nakagawa, M. (2009) · Acta Neuropathologica · doi:10.1007/s00401-008-0456-1 · Cited by 211
“Recently, the 43-kDa transactive response (TAR)-DNAbinding protein (TDP-43), which is encoded by the TARDBP gene on chromosome 1, was identiWed as the major pathological protein of the motor neuron inclusions found in SALS and SOD1-negative FALS, as well as sporadic and familial FTLD with UBIs (FTLD-U) [2, 7, 8, 14, 1…”
InfluentialYu, C.-E., Bird, T. D., Bekris, L. M., Montine, T. J., Leverenz, J. B., Steinbart, E., Galloway, N. M., Feldman, H., Woltjer, R., Miller, C. A., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2009.328 · Cited by 190
Caccamo, A., Majumder, S., Deng, J. J., Bai, Y., Thornton, F. B., & Oddo, S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.031278 · Cited by 169
Synergistic effect between proteasome and autophagosome in the clearance of polyubiquitinated TDP‐43
Urushitani, M., Sato, T., Bamba, H., Hisa, Y., & Tooyama, I. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22243 · Cited by 114
Zhang, H., Tan, C.-F., Mori, F., Tanji, K., Kakita, A., Takahashi, H., & Wakabayashi, K. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0285-7 · Cited by 111
“Recent studies using TDP-43 immunohistochemistry have shown that TDP-43-positive inclusions were found in the neostriatal small neurons in ALS [43], FTLD-U [12, 40], and hippocampal sclerosis [2].”
InfluentialPearson, J. P., Williams, N. M., Majounie, E., Waite, A., Stott, J., Newsway, V., Murray, A., Hernandez, D., Guerreiro, R., Singleton, A. B., et al. (2011) · Journal of Neurology · doi:10.1007/s00415-010-5815-x · Cited by 84
Hiji, M., Takahashi, T., Fukuba, H., Yamashita, H., Kohriyama, T., & Matsumoto, M. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0402-2 · Cited by 68
Metadata
- Authors
- Seelaar, H., Jurgen Schelhaas, H., Azmani, A., Kusters, B., Rosso, S., Majoor-Krakauer, D., de Rijik, M. C., Rizzu, P., ten Brummelhuis, M., van Doorn, P. A., Kamphorst, W., Willemsen, R., & van Swieten, J. C.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-04-02
- Volume
- 130
- Issue
- 5
- Pages
- 1375-1385
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2113002389
- Cited by
- 96
- References
- 8
- FWCI
- 9.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.